U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07556822) titled 'Phase I Study of HRS-3005 in B-cell Malignancies' on April 14.
Brief Summary: The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-3005 in patients with B-cell malignancy.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
B-cell Malignancy
Intervention:
DRUG: HRS-3005
HRS-3005
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Published by HT Digital Content Services with permission from H...